A multicenter, open-label phase trial reports promising activity for a combination approach in unresectable liver cancer using cadonilimab, lenvatinib and TACE. The study focuses on hepatocellular carcinoma patients whose tumors remain confined to the liver but cannot be removed surgically. The report signals a continuing attempt to integrate immunotherapy with locoregional procedures (TACE) and VEGF-pathway inhibition (lenvatinib), aiming to broaden response rates and deepen disease control in difficult-to-resect populations. For biotech and clinicians, the data supports further evaluation of combination sequencing and safety management in trials that seek to improve outcomes without requiring transplant or resection.